Some patients recognise their angina like an old friend, greeting them after a fixed amount of effort. For others cardiac pain comes out of the blue, heralding myocardial infarction. In between these two well defined manifestations of coronary disease lies the syndrome of unstable angina; it may be formally defined as angina increasing in frequency, intensity, or duration, or rest pain lasting for at least 15 minutes without evidence of infarction. ' Informally patients complain that their pains have become unpredictable.
Nothing exceptional is to be seen in the angiographic pattern of coronary artery disease in patients who have suffered unstable angina,24 but angiograms taken before and after the episode are more likely to show progression of the disease than control films taken from patients whose angina has remained stable.56 If angiography is undertaken during an attack of unstable angina the appearance of the coronary lesions may be unusual in that the stenoses seem eccentric with irregular borders7 and, sometimes, with intraluminal thrombus.8 These angiographic appearances correlate with the pathological complications of atheroma such as rupture of plaques and of thrombus formation.9 Necropsy examination of patients who have died suddenly with what their relatives describe as episodic chest pain has confirmed that the basis for this syndrome is likely to be change in an atheromatous plaque, with rupture or fissuring of the covering endothelium."' This study also showed platelet emboli in the myocardium downstream from the atheroma, suggesting that unstable angina may be the cardiac equivalent of transient cerebral ischaemic attacks associated with carotid atheroma.'0 What actually triggers the onset of unstable angina or fissuring of the coronary atheroma is uncertain. A reduction in coronary flow has been shown in angina at rest," and this may be due to vasospasm.'2 The evidence that platelets may play a part in the aetiology is rather more convincing, both because intracoronary thrombi are present in unstable angina" 10 and because altered platelet behaviour can be shown in coronary disease'3 and acute vascular events. ' In patients with unstable angina increased concentrations of the platelet specific protein ,B thromboglobulin are found in peripheral blood,'" and there is a rise in the concentration in the coronary sinus of thromboxane B2, another indicator of platelet activity. '6 Possibly spasm of the healthy part of a coronary artery ( BRITISH MEDICAL JOURNAL 1986. All reproduction rights reserved.
containing an eccentric atheromatous plaque may cause cracking of the plaque surface, aggregation of platelets, new thrombus formation, further occlusion of the lumen, reduction in flow, and distal platelet emboli leading to cardiac pain. Given that this sequence ofevents is correct the next question becomes whether it should affect management.
The first task in the management of patients with unstable angina is to relieve their pain and anxiety. Rest, nitrates, 1B blockade, and some sedation achieve these aims-largely by reducing cardiac work, though nitrates will also reverse any coronary spasm. Urgent angiography (with a view to angioplasty or bypass surgery) is being recommended and practised with enthusiasm in the United States, Germany, and some centres in Britain.'7 Dramatic results may apparently be achieved, but this energetic (and expensive) practice cannot be recommended on the strength of published experience. Angioplasty and surgery should be reserved for those patients with persisting angina despite full medical treatment.
The second task is to improve prognosis after the acute episode. In Fulton's classic study of 167 patients with unstable angina 23 went on to develop cardiac infarction and five died within three months.'8 Other studies have confirmed that most patients will survive in good health, but the mortality after one year is still a worrying 10%'7 920; a few more patients will suffer myocardial infarction and survive but with a poorer prognosis. Attempts to identify those most at risk have proved disappointing.21 Among the clinical predictors recurrent pain seems to be a clue,20 thus reinforcing the need for angiography in these patients.
The belief that platelets may play a part in the aetiology of unstable angina has prompted the use of drugs, such as heparin and aspirin, which modify platelet behaviour. The clinical impression that heparin helps in the management of the acute symptoms has received support from the work of Telford and Wilson, who showed that patients receiving heparin were less likely to develop myocardial infarction in hospital. 22 angina.
I" Both studies were multicentre, randomised, and double blind. In the Veterans' Administration study of 1266 men buffered aspirin 325 mg daily was compared with placebo,' whereas in the Canadian study the 555 patients received aspirin 1300 mg daily, sulfinpyrazone 800 mg daily, or both, or neither.24 Patients were entered into the trials by 51 hours and eight days after admission respectively. In the Veterans' study there was a 51% reduction in death or acute myocardial infarction in the active treatment group at 12 weeks. The Canadian study found an identical reduction in the aspirin treated groups compared with the others after 18 months' follow up; the absolute numbers in the groups receiving aspirin either alone or in combination were 17 cardiac deaths or non-fatal myocardial infarcts out of a total of276 patients compared with 36 events in 279 patients in the other groups. In both studies the patient groups were comparable and similar to those patients seen elsewhere; for example, the mortality for the untreated patients in the Veterans' study who were followed up for one year was 9 6%.
In both studies withdrawals were few, and the incidence of side effects in the various groups was similar apart from the increased frequency of gastrointestinal symptoms in those taking aspirin in the Canadian study.
So for our patients with unstable angina medical management remains appropriate; only those with persisting pain need be referred for angiography. For subsequ-ent treatment a credible maxim might be that a coated or buffered aspirin a day keeps the coronary at bay.
M C PETCH Consultant Cardiologist, Regional Cardiac Centre, Papworth Hospital, Cambridge CB3 8RE
Use of molar units for drugs and toxins?
The chemical, physiological, and pharmacological activity of any natural or artificial constituent of body fluids (and its comparison with the activity ofsimilar constituents) is almost always directly related to the concentrations of the relevant molecules, radicals, or ions expressed in amount ofsubstance (mole) units, and not to the concentrations in mass units such as grams. The BMJ made the change from using mass concentrations to (amount of) substance concentrations in 1975; but this change implies more than just a switch in numerical values, as in converting from calories to joules. The use of molar units requires a conceptual change in dimensions, for when using moles we are in effect counting the number of relevant functioning entities-for example, one molecule, one receptor site. Both substance concentrations and mass concentrations-usually per litre, are part of the Systeme International d'Unites (SI), each to be used when most appropriate; in popular medical jargon, however, "SI" has come to mean the preferential use of substance concentrations, typically as mmol/l. In most medically advanced countries, including Britain, the results of assay of almost all substances in plasma (or other body fluids) are quoted as substance concentrations if they are naturally occurring constituents of the body and have a known relative molecular mass. The main exception has been the plasma proteins, but the changeover has started for them. There has been no move to abandon the advantages ofthis system and return to mass units, for this would now be regarded as a retrograde step; the biological importance of the concept ofthe mole is taught from schooldays. The initial British recommendations did not, however, give guidance for plasma (or urine) constituents that were not normally present, particularly drugs and toxins.' So we have the anomaly that in patients plasma lactate and cholesterol concentrations, for example, are measured in mmol/l, while plasma salicylate and ethanol concentrations are usually measured in mg/dl-and some drug concentrations are confusingly given per millilitre. In pharmacological research substance concentrations for drugs are already widely used, particularly in experimental animals.
In the United States the American Medical Association has now decided to recommend the change from using mass concentrations to substance concentrations.2 These intentions will extend both to natural constituents and to drugs. The time seems right, therefore, to plan the change for drug and toxin concentrations in Britain,3 and the Association of Clinical Biochemists has issued recommendations for drugs. 4 These read: "Rationalisation is paramount in the interests of patient safety. The units adopted should be based on the litre as the unit of volume. As no particular unit is used by a substantial majority of laboratories, molar units should be the units of choice because of the strong scientific arguments in their favour."
